Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?

Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now, there are exciting late-phase clinic... Author: VJOncology Added: 02/09/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts